Table
3: Phase III trials with
improved overall survival in second-line treatment.
Trial |
N |
Treatment |
ECOG
PS |
PFS |
OS |
TAX317 Shepherd et
al. JCO 2000 [24] |
204 |
Docetaxel vs. BSC |
0-2 |
10.6 vs. 6.7 weeks (TTP), p = 0.001 |
7.0 vs. 4.6 months, p
= 0.047 |
Hanna et al. JCO 2004 [25] |
571 |
Pemetrexed vs. docetaxel |
0-2 |
2.9 vs. 2.9 months |
8.3 vs. 7.9 months |
BR.21 Shepherd et
al. NEJM 2005 [27] |
731 |
Erlotinib vs. placebo (2nd or 3rd
line) |
0-3 |
2.2 vs. 1.8 months, p <
0.001 |
6.7 vs. 4.7 months, p <
0.001 |
INTEREST Kim et al.
Lancet 2008 [29] |
1466 |
Gefitinib vs. docetaxel (2nd or 3rd
line) |
0-2 |
2.2 vs. 2.7 months, p
= 0.47 |
7.6 vs. 8.0 months, p = 0.50 (non-inferior) |
LUME-Lung 1 Reck et
al. Lancet Oncol 2014 [36] |
655 |
Docetaxel + nintedanib vs. docetaxel +
placebo |
0-1 |
3.4 vs. 2.7 months, p
= 0.0019 |
10.1 vs. 9.1 months, p
= 0.2720 (12.6 vs. 10.3 mosinpts with adenoCa, p = 0.036) |
REVEL Garon et al.
Lancet 2014 [37] |
1253 |
Docetaxel + ramucirumab vs. docetaxel +
placebo |
0-1 |
4.5 vs. 3.0 months, p <
0.0001 |
10.5 vs. 9.1 months, p
= 0.023 |
CheckMate 017 Brahmer et al.
NEJM 2015 [48] |
272 |
Nivolumab vs. docetaxel (squamous cell
carcinoma) |
0-1 |
3.5 vs. 2.8 months, p =
0.008 |
9.2 vs. 6.0 months, p <
0.001 |
CheckMate 057 Borghaei et
al. NEJM 2015 [49] |
582 |
Nivolumab vs. docetaxel (non-squamous NSCLC) |
0-1 |
2.3 vs. 4.2 months, p
= NR |
12.2 vs. 9.4 months, p = 0.002 |
KEYNOTE-010 Herbst et al. Lancet 2015 [50] |
1034 |
Pembrolizumab 2 mg/kg vs. 10 mg/kg vs.
docetaxel |
0-1 |
3.9 vs. 4.0 vs. 4.0 months p = NS |
10.4 vs. 12.7 vs. 8.5 months, 2 mg/kg vs. D: p = 0.0008, 10 mg/kg vs. D: p < 0.0001, 2 vs. 10: p
= NS |
LUX-Lung 8 Soria et
al. Lancet Oncol 2015 [33] |
795 |
Afatinib vs. erlotinib (squamous cell) |
0-1 |
2.4 vs. 1.9 months, |
7.9 vs. 6.8 months, p
= 0.0077 |